Inflammation plays a critical role in mediating brain injury induced by neonatal hypoxic ischemic encephalopathy (HIE). The mechanisms underlying inflammatory responses to ischemia may be shared by neonatal and adult brains; however, HIE exhibits a unique inflammation phenotype that results from the immaturity of the neonatal immune system. This review will discuss the current knowledge concerning systemic and local inflammatory responses in the acute and subacute stages of HIE. The key components of inflammation, including immune cells, adhesion molecules, cytokines, chemokines and oxidative stress, will be reviewed, and the differences between neonatal and adult inflammatory responses to cerebral ischemic injury will also be discussed.
Perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal death and long-term disability. Approximately 15% to 25% of affected newborns die in the postnatal period and 25% develop severe and permanent neuropsychological sequelae1, including cerebral palsy, seizures, visual impairment, mental retardation, learning impairment and epilepsy2. Two phases of HIE-induced neuronal death have been identified in both clinical and experimental studies3,4,5. The immediate phase, primary neuronal death, is related to cellular hypoxia with exhaustion of the cell's high-energy stores (primary energy failure). The second phase, delayed neuronal death6, occurs after a latent period of at least six hours, and is associated with encephalopathy and increased seizure activity. Delayed neuronal death accounts for a significant proportion of final cell loss even after very severe insults. The mechanisms involved in delayed neuronal death include excitotoxicity, apoptosis and microglial activation7. Microglia are the resident immune cells in the brain, and microglial activation is the initial step in inflammatory responses of the central nervous system (CNS) to various stimuli, including stroke8. This initial step is followed by the infiltration of circulating monocytes, neutrophils and T-cells9, which amplifies the inflammatory response in a stimulated brain.
Cerebral ischemia induces an inflammatory response in both the parenchyma and the systemic circulation. Within hours after an insult to the brain of an adult, cytokines are produced in large amounts, and leukocytes are activated and migrate into the injured brain10,11,12,13,14. In neonates, however, cerebral ischemia initiates an immediate innate immune response even minutes after the insult15. Age differences in the mechanisms of stroke, some of them very striking, stem from immaturity of the CNS, including differences in the cross-talk between excitotoxic, oxidative and inflammatory injury mechanisms, creating “windows of susceptibility” to hypoxic-ischemic injury during embryonic and early postnatal brain development16. Here, we review the data on specific aspects of neuroinflammation in the acute and subacute stages of HIE, and will also introduce known similarities and differences in adult and neonatal cerebral ischemic injury. Because the chronic inflammatory response to HIE may last for years and varies according to the developmental stage of the brain, this topic is beyond the scope of this review and will not be discussed.
Microglia are a major glial component of the CNS and provide immuno-surveillance in the brain17. Resting microglia in a healthy brain, known as surveying microglia, are constantly extending and retracting their thin ramified processes to inspect the CNS microenvironment18,19. When an ischemic event occurs, microglia are activated and develop macrophage-like abilities including phagocytosis, the production of inflammatory and anti-inflammatory cytokines, antigen presentation and the release of matrix metalloproteinases (MMPs), which lead to blood-brain barrier (BBB) breakdown20. As a result, peripheral leukocytes infiltrate the brain, and the normally immune-privileged brain environment is exposed to systemic responses that further exacerbate inflammation and brain damage (Figure 1). The innate immune response is characterized by the classical activation (M1) of microglia and the subsequent production of specific cytokines, chemokines and reactive intermediates, followed by resolution and alternative activation (M2) that leads to anti-inflammatory signaling (M2a), the clearance of reactive oxygen (ROS) and nitrogen (RNS) species (M2b), and wound healing (M2c)21. During disease progression, microglial activation phenotypes switch from M1 to M2 or vice versa depending on inflammatory signaling22. The M1 phenotype of microglia can lead to increased neuronal death compared to the alternatively activated M2 microglial phenotype23; therefore, there is a growing interest in controlling the classical activation phenotype of microglia.
In addition to microglia, macrophages also inhabit various regions (choroid plexus, peri-vasculature and meninges) of the CNS24. The heterogeneous population of tissue macrophages can be continuously replenished by circulating monocytes, unlike microglia, which are thought to reside in the adult CNS from early development25,26,27. The theory that a second wave of microglia is established in the brain during the postembryonic period and is derived from peripheral monocytic precursors that last into adulthood is a subject of ongoing debate25,28. However, one recent study suggested that a population of dying microglia in the ischemic brain could be replenished by peripheral monocytes or macrophages infiltrating the injured region and then acquiring microglial phenotypes29.
Microglial activation and aggregation are pathological markers for HIE in human infants30. Retrospective clinical studies on the postmortem examinations of 178 brains from neonates found that patients who died from HIE had a dense infiltrate of microglia in the hippocampal dentate gyrus, whereas those neonates who died of other acute causes (trauma or sepsis) had significantly fewer microglia30. Emerging experimental data from disease models also outline the importance of microglial activation in hypoxia-induced neuroinflammation. HIE in preterm sheep resulted in profound activation and proliferation of microglia in the hippocampus and the periventricular and subcortical white matter, followed by a significant influx of neutrophils into the brain31. Ameboid microglia in the developing brain respond vigorously to hypoxia and accumulate in injured tissue32,33,34,35, producing excess amounts of inflammatory cytokines (TNF-α, IL-1β, etc) along with glutamate, nitric oxide (NO) and ROS, which collectively cause oligodendrocyte death, axonal degeneration and disruption of the immature BBB32,33,36. Compared to adults, microglial activation in neonates is much more rapid following transient ischemia37,38 and excitotoxic injury39 and continues for weeks39,40,41.
Both astrocytes and microglia are activated within minutes after injury by pro-inflammatory mediators, cytokines, and ROS that are secreted by injured neurons and glial cells42. The activation of astrocytes has both detrimental and beneficial roles in brain ischemia. Astrocyte support of neurons after a stroke can be achieved by several mechanisms, including the release of glutathione and superoxide dismutase (SOD)43,44,45, enhanced extra-synaptic glutamate uptake46,47,48, and the maintenance of ion gradients, such as that for potassium49,50. However, activated astrocytes can also produce pro-inflammatory cytokines, including IL-6, TNF-α, IL-1α, and β and interferon γ42,51,52. Rapid increases in the levels of these cytokines exacerbate an ischemic injury by directly inducing the apoptosis of neuronal cells53, increasing toxic NO levels and inhibiting neurogenesis54. Apart from cytokines, reactive astrocytes also secrete chemokines after ischemia, which results in the attraction of immune cells to the ischemic site and worsening of the brain injury55,56.
In the brains of human neonates, astrocytes do not readily become reactive and responsive to injury signals until 20 to 23 weeks of gestation57. Experimental studies regarding astrocytic responses to HIE or systemic LPS stimulation performed in fetuses from various species, eg, lamb58,59,60, baboon61, and kitten62, found astrocyte hypertrophy and hyperplasia. These studies concluded that astrocytes generally are resistant to damage during the neonatal period and that the astrocytes adjacent to regions of necrosis are ready to proliferate. Similar to the findings in adult ischemic models, astrocytes in P7 rat neonates are rarely observed within the ischemic core but are abundant in the penumbra area 24 h after HIE37. One unique role of neonatal astrocytes in HIE-induced inflammatory responses is that, in addition to the self-release of cytokines and chemokines, reactive astrocytes in neonatal brains have the ability to up-regulate the expression of inflammatory mediators in neuroblasts and angioblasts, which are chemotactic for bone marrow-derived immune cells63.
During ischemia, neutrophils can exacerbate brain injury through multiple mechanisms, including ROS production35, decreased microvascular flow resulting from capillary plugging by neutrophils64, the enhanced release of cytoxic agents into the vasculature and brain parenchyma65,66, and MMP-9 secretion67. The accumulation of neutrophils in ischemic brain tissue occurs as early as 4 h to 6 h after the onset of ischemia in adult animals65,68,69,70 and lasts to 48 h post insult, during the period while the brain injury is evolving71,72,73. In contrast to the exacerbated neutrophil infiltration observed in adults, neonates have a diminished ability to mount a neutrophil response to ischemia. Neonatal neutrophils show reduced extravasation from blood vessels74,75. A previous study has shown that neutrophils did not transmigrate into the brains of P7 rats following HI injury within 42 h and were almost exclusively intravascular at all time periods examined76. Similarly, it has been reported that neutrophils were most often found within vessels and only transiently invaded brain tissue in the infarct region after induction by HI in P7 rats35. These studies indicated that neutrophils do not accumulate in ischemic brain parenchyma in neonatal rodents to the extent that they do in adults. Interestingly this concept translated well into the neuroprotection achieved with anti-neutrophil strategies; treatment with neutrophil inhibitory factor initiated after HI insult was neuroprotective in adult animals77,78,79 but was less efficacious in neonatal rats. Beneficial effects were only observed when neutropenia was induced before the HI insult80, making this a less clinically relevant target for treating neonatal injury.
Generally, lymphocytes are thought to play a negative role in acute ischemic brain pathogenesis. Yilmaz et al81 reported that Rag1−/− mice, deficient in both T cells and B cells, had significantly smaller infarcts and neurologic damage compared to WT mice when subjected to middle cerebral artery occlusion (MCAO). In the same study, Rag1−/− mice reconstituted with splenocytes from WT mice were no longer protected from stroke, suggesting that the peripheral lymphocytic response plays an important role in mediating post-stroke injury. Infiltration of T cells and B cells into the ischemic brain can be observed as early as a few hours82,83, and lasts days after injury in adult rodents84,85. However, in neonates the infiltration of these cells following HIE and focal stroke may be less profound35,86 or only briefly present in the parenchyma87. The minimal involvement of lymphocytes in ischemia-induced inflammatory responses in the neonatal brain may reflect the immaturity of lymphoid progenitor cells. Recent clinical studies showed that peripheral blood mononuclear cells of newborns are relatively undifferentiated and have a very low expression level of surface markers88. There are few studies investigating the role of lymphocytes in HIE. It is likely that a lymphocytic response is involved in the more chronic immunoinflammatory activation following HIE; the Hagberg group35 found that CD4 lymphocytes invaded the infarct region quite late after injury (7 d after HIE) and persisted in damaged areas for 14 d to 35 d. Whether this lymphocytic response enhances damage or, conversely, enhances post-stroke repair is not yet clear. It is also unknown whether the presence of lymphocytes can lead to the development of later CNS autoimmunity, as has been observed in adult injury models89.
The recruitment of leukocytes in the cerebral vasculature and the subsequent migration to the ischemic brain tissue are initially mediated by three main groups of cell adhesion molecules: selectins, the immunoglobulin superfamily and integrins90. The recruitment process involves two stepwise stages, ie, an initial low affinity binding that is manifested as rolling and a later high affinity interaction that results in firm adhesion. Adhesion molecules may represent important therapeutic targets because inhibiting leukocyte adhesion with antibodies or inhibitors has improved histological and neurological outcomes in experimental stroke studies, whereas over-expression of adhesion molecules resulted in the exacerbation of infarcts91. Very few neonatal studies have reported the role of and changes in adhesion molecules in HIE; we have summarized the available data from studies in both HIE and other inflammatory diseases in Table 1.
Selectins play a key role in the early (rolling) stages of leukocyte/endothelial interactions in the ischemic cerebral microvasculature. Although all three selectins, L-, P-, and E-selectin, have been implicated in neutrophil rolling, P-selectin is the most important during the initial induction of neutrophil rolling after endothelial cell stimulation92. Compared to adults, decreased P-selectin expression in neonates has been found in activated platelets93 and endothelial cells94. Similarly, L-selectin expression in term infant neutrophils is significantly lower than that in adult neutrophils either stimulated or unstimulated95. This may explain why the decreased adhesion of neutrophils to endothelial cells and delayed transendothelial cell migration of neutrophils have been consistently reported in neonatal animals and humans and may also contribute to susceptibility of neonates to infection96,97. In immature animal brains during acute inflammation, E-selectin seems less important than other selectins because the blockade of E-selectin has no effect on neutrophil recruitment to the brain parenchyma, whereas the administration of P-selectin blocking monoclonal antibody inhibited neutrophil recruitment by 85% compared with controls98.
Integrins and the immunoglobulin superfamily
The firm adhesion of leukocytes to the endothelium after rolling requires the activation and binding of leukocyte-expressed integrins to endothelial adhesion molecules99. Integrins are heterodimers consisting of a common β subunit and a variable α subunit100. The major integrins expressed on neutrophils are the β2 integrins LFA-1 (αLβ2, CD11a/CD18) and Mac-1 (αMβ2, CD11b/CD18). Monocytes adhere through the β1 integrins VLA-4 (α4β1, CD49d/CD29). To form a firm adhesion, integrins must bind to counter-receptors of the immunoglobulin superfamily expressed on inflamed endothelial cells, including ICAM-1, ICAM-2, VCAM-1, the mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), platelet-endothelial cell adhesion molecule-1 (PECAM-1), and the receptor for advanced glycation end products (RAGE)101,102,103. Although no age-related differences in basal and stimulated LFA-1 surface expression were found in human neonatal and adult neutrophils104,105,106,107,108, Mac-1 expression remains low during the prenatal and postnatal periods and reaches adult levels by 11 months108,109. The lower surface expression of Mac-1 on neonatal neutrophils has been directly linked to impaired transendothelial migration under chemotactic stimulation75,110 (Table 1).
Thus far, no data are available in neonates regarding the roles of integrins and the immunoglobulin superfamily in HIE. Experimental studies with adult stroke models have shown that blockade of LFA-1/Mac-1111,112,113,114,115 and ICAM-1116,117 had beneficial effects on stroke outcomes. However, clinical trials of stroke patients given humanized antibodies against these adhesion molecules showed no effect118,119 or a worse outcome120. There are several reasons (see review121) for the failure of antibodies against these adhesion molecules to translate into a clinically relevant treatment strategy. For example, the study designs in the clinical trials did not mirror the laboratory models (such as late treatment or the absence of documented recanalization to the occluded vessel). Another possibility is that changes in neutrophil integrins are different between humans and rodents. Indeed, recent work has highlighted the differences in the immune system between species122. These differences emphasize the importance of clinical biomarkers and early phase studies to confirm the targets in both adult stroke and neonatal HIE, particularly using accessible sources such as peripheral blood. Although intervention strategies targeting adhesion molecules appeared to be effective in preclinical studies, moving this work into humans remains a tremendous challenge. It is encouraging that natalizumab, a humanized monoclonal antibody against α4-integrin, has been used to treat multiple sclerosis for more than 5 years123 and has been reported to decrease the risk of disability progression by 42% to 54% and to reduce the annualized rate of relapse by 68%124. Natalizumab treatment is associated with a risk of progressive multifocal leukoencephalopathy (PML), an opportunistic brain infection caused by the JC virus125. However, because its clinical benefits outweigh the risks involved, natalizumab remains on the market in the US under a special prescription program using risk stratification algorithms and PML management strategies123.
Cytokines are important inflammatory mediators, and cerebral ischemic injury can trigger a cascade of cytokine induction that acts to orchestrate an in situ inflammatory reaction133 and maintains brain tissue homeostasis134. In general, the roles of cytokines are pleiotropic, and whether the overall effects are pro- or anti-inflammatory in the context of ischemic insults remains controversial even in adult models, for which there are more data than for HIE. The most studied cytokines related to the inflammatory responses to stroke are IL-1, IL-6, IL-10, tumor necrosis factor-α (TNF-α), and transforming growth factor-β (TGF-β)135.
IL-1β and TNF-α are among the best-characterized early response cytokines and are often expressed concurrently136. Several types of CNS cells secrete IL-1β and TNF-α, including microglia, astrocytes, and neurons, and these cytokines share potent pro-inflammatory actions. Human newborns with HIE have higher levels of IL-1β and TNF-α in peripheral blood samples at P1, P3, and P7 compared to controls, and the IL-1β levels correlate positively with HIE severity137. The neurotoxic consequences of IL-1 activation have been shown in experimental studies with HIE138,139,140 and other inflammatory disease models141,142,143. The most convincing evidence that IL-1 is functionally detrimental in the pathogenesis of HIE is provided by the neuroprotective potential of IL-1 receptor antagonist administration in HIE models in rodents144,145 (Table 2).
Chemokines, or chemoattractant cytokines, also play a pivotal role in cerebral damage in ischemic stroke, HIE and excitotoxic brain injury models146. Chemokines are classified based on the positions of key cysteine residues (C): C, CC, CXC, and CX3C, and act through specific and shared receptors belonging to the superfamily of G-protein-coupled receptors147. As their name indicates, chemokines play a central role in leukocyte physiology by controlling inflammatory cell trafficking. HIE modeled in P7 rats induces the up-regulation of alpha-chemokines [growth related gene and macrophage inflammatory protein-2 (MIP-2)] and beta-chemokines (MIP-1α, MIP-1β, CCL-5) preceding the expression of markers for lymphocytes in the infarcted area35. In the neonatal brain, acute excitotoxic injury stimulates the expression of both monocyte chemotactic protein-1 [MCP-1, also called chemokine ligand 2 (CCL2)] and its receptor CCR2, suggesting that MCP-1 regulates the microglial/monocyte response to acute brain injury and contributes to the pathogenesis of acute neonatal brain injury148,149. This has been confirmed by another study using the same model in which anti-MCP-1 antibody attenuated tissue injury in neonatal rats150 (Table 2). Few data are available on the potential role of CXC chemokines in perinatal stroke. In experimental adult stroke models, stromal cell-derived factor 1 (SDF-1 or CXCL12) is expressed perivascularly in the injured region up to 30 d after the injury, suggesting that it could be a therapeutic target for tissue repair strategies151. However, in P7 mice, stroke induced up-regulation of CXCL12 was only observed up to 7 d after the injury but not at a later time point63, indicating a significantly smaller temporal window for CXCL12-mediated repair after a perinatal stroke.
Oxidative stress has recently been recognized as a common pathway in which different inflammatory cells mediate post-ischemic injury159,160. After ischemic insults, the inflammatory cells in the brain are activated and then generate ROS via several enzyme systems to induce the expression of pro-inflammatory mediators including cytokines and adhesion molecules160. Superoxide is generated via cyclo-oxygenase (COX), xanthine dehydrogenase, xanthine oxidase, and NADPH oxidase, whereas myeloperoxidase (MPO) and monoamine oxidase (MAO) generate hypochlorous acid and H2O2121. Compared to adult mice, P7 pups show the increased accumulation of H2O2 in the brain after a HI injury, suggesting that the neonatal brain may be more damaged even after a milder degree of acute hypoxic-ischemic injury161 (Table 3). Glutathione peroxidase (GPX) is a key enzyme responsible for the degradation of H2O2162. The neonatal brain has limited GPX activity and is more susceptible to oxidative damage, as described in a study showing that H2O2 rapidly accumulates in human-superoxide dismutase-1 (hSOD1) transgenic P7 mice, thus resulting in exacerbated HI brain injury, which is reversed in hGPX1-Tg mice163. However, the role of ROS in neonatal inflammatory responses following HIE is controversial. Inhibition of NADPH oxidase, the most important source of ROS164, increases HI injury and the level of IL-1β in P9 mice165. In contrast, it has been well established that NADPH oxidase can exacerbate inflammatory responses and stroke outcomes in adult animal models (see review166). Therefore, the results obtained in adult animals are not completely relevant to newborns and the role of oxidative stress in HIE remains to be fully investigated.
Fetal inflammatory response syndrome (FIRS)
Originally defined in fetuses who experienced preterm labor and preterm premature rupture of the membranes (PROM), FIRS is a unique condition characterized by the systemic activation of the fetal innate immune system and by an elevation in fetal plasma IL-6 concentrations171. Currently, FIRS is characterized by a rapid increase in pro-inflammatory signaling (cytokines, chemokines, etc) and the mobilization of immune effector cells into the fetal circulation172. These pro-inflammatory mediators readily cross the BBB and induce the activation of microglia, which initiates a detrimental cerebral inflammatory response. The unique circumstances of the “patient” (fetus) and the environment (uterus) in FIRS make it distinguishable from other diseases; however, by definition, FIRS and inflammatory responses after HIE partly overlap in pathophysiology, and they share similar inflammatory mechanisms in the brain. There are multiple putative mechanisms by which the neonatal brain can sense FIRS signals in the systemic circulation, which will then lead to neuroinflammation. These mechanisms include the interface of macrophages in the circumventricular brain area, without a BBB, with circulating inflammatory molecules173, and the direct access of FIRS signals into the CNS through leakage of the BBB in the setting of peripheral inflammatory pain signaling through the vagal nerve174. The manner in which FIRS influences the response to HIE and whether HIE can induce FIRS and subsequent peripheral immune activation is an area of active study.
HIE triggers a robust inflammatory response and accumulating data have linked post-ischemic inflammation to the exacerbation of brain damage. Many inflammatory mechanisms and pathways after cerebral ischemia have been assessed in various studies performed in adult subjects; however, caution should be exercised when attempting to extrapolate these findings to neonates. The mechanisms underlying cerebral ischemic injury and the following immune response are likely very different between the neonates and the adults.
This work was supported by the NIH/NINDS (grants NS050505 and NS055215 to Louise D MCCULLOUGH), and by the American Heart Association (grant 12SDG9030000 to Fudong LIU)
This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/